Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Ends Rilotumumab Development in Gastric Cancer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Amgen Ends Rilotumumab Development in Gastric Cancer

Safety review finds increased number in deaths in the rilotumumab treatment arm

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen has terminated all of its clinical studies of rilotumumab in advanced gastric cancer based on a planned safety review by the RILOMET-1 independent data monitoring committee, which found an increase in the number of deaths in the rilotumumab and chemotherapy treatment arm compared to the chemotherapy treatment only arm.
 
“While we are disappointed with these results, we will work with lead investigators to further analyze the data in order to help inform future research and therapies in this area,” said Sean E. Harper, M.D., executive vice president of R&D at Amgen.  “There is a high unmet need for new treatments to address advanced gastric cancer, one of the leading causes of cancer death worldwide.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics